FDA OKs U.S. trial for Alphamab Oncology's HER2 bispecific antibody

Alphamab Oncology (Suzhou, China) said it received clearance from FDA to begin a U.S. Phase I trial of KN026, a HER2 bispecific antibody.

Alphamab Oncology Chairman and CEO Ting Xu said in a statement that this is the first U.S. IND approval for a bispecific antibody discovered and developed by China-based biotechs or pharmas. The company plans to start the trial next year...